International experts report findings on incontinence
Paris-Many therapies for urinary incontinence continue to suffer from a lack of definitive data from well-controlled clinical trials, according to a panel of experts convened by a group of international health organizations. Their findings were reported here at the Second International Consultation on Incontinence, which was sponsored by the World Health Organization International and organized by the International Consultation on Urological Diseases and the International Continence Society.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.